Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22019290 | 0.88 | ATM (0.36) | KCNQ3KCNQ2ATM | |
| SCHEMBL22959711 | 0.88 | ATM (0.36) | KCNQ3KCNQ2ATM | |
| SCHEMBL21673377 | 0.85 | ACHE (0.35) | KCNQ3KCNQ2KCNH2 | |
| SCHEMBL21935513 | 0.84 | — | — | |
| SCHEMBL24856129 | 0.81 | — | — | |
| SCHEMBL21933953 | 0.81 | — | — | |
| SCHEMBL21934615 | 0.81 | — | — | |
| SCHEMBL25143750 | 0.77 | ACHE (0.32) | — | |
| SCHEMBL16640662 | 0.77 | ATM (0.45) | ATM | |
| SCHEMBL737451 | 0.75 | HRH3 (0.50) | CHRM2HTR1AADRA2ACYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002348-A1 | GLP-1 Receptor Agonist and Use Thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | COGNITION THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | COGNITION THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | GENOSCIENCE PHARMA (FR) | 2020-03-03 | — | — | US | disclosed |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2019-05-16 | — | — | US | disclosed |
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002348-A1 | GLP-1 Receptor Agonist and Use Thereof | GLP1R, GIPR, GPR119 | KCNQ3 1078/4885KCNQ2 1369/4885CHRM2 1736/4885 |
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | KCNQ3 4661/4885KCNQ2 4573/4885CHRM2 1610/4885 |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | NQO2, RECQL, CCNO | KCNQ3 2600/4885KCNQ2 1888/4885CHRM2 3261/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | KCNQ3 4874/4885KCNQ2 4877/4885CHRM2 4720/4885 |
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | NLN, GAP43, PSEN2 | KCNQ3 3547/4885KCNQ2 3479/4885CHRM2 548/4885 |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | NQO2, RECQL, CCNO | KCNQ3 2600/4885KCNQ2 1888/4885CHRM2 3261/4885 |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | GAP43, NLN, SNAP29 | KCNQ3 2766/4885KCNQ2 2705/4885CHRM2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.